| DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis F Sahm, D Schrimpf, D Stichel, DTW Jones, T Hielscher, S Schefzyk, ... The lancet oncology 18 (5), 682-694, 2017 | 780 | 2017 |
| Advances in the molecular genetics of gliomas—implications for classification and therapy G Reifenberger, HG Wirsching, CB Knobbe-Thomsen, M Weller Nature reviews Clinical oncology 14 (7), 434-452, 2017 | 678 | 2017 |
| Glioblastoma HG Wirsching, M Weller Malignant Brain Tumors: State-of-the-Art Treatment, 265-288, 2017 | 574 | 2017 |
| MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial M Weller, G Tabatabai, B Kästner, J Felsberg, JP Steinbach, A Wick, ... Clinical cancer research 21 (9), 2057-2064, 2015 | 386 | 2015 |
| Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial B Suchorska, M Weller, G Tabatabai, C Senft, P Hau, MC Sabel, ... Neuro-oncology 18 (4), 549-556, 2016 | 278 | 2016 |
| CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas P Sievers, T Hielscher, D Schrimpf, D Stichel, DE Reuss, AS Berghoff, ... Acta neuropathologica 140, 409-413, 2020 | 179 | 2020 |
| Integrated molecular-morphologic meningioma classification: a multicenter retrospective analysis, retrospectively and prospectively validated SLN Maas, D Stichel, T Hielscher, P Sievers, AS Berghoff, D Schrimpf, ... Journal of clinical oncology 39 (34), 3839-3852, 2021 | 163 | 2021 |
| Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence LM Katz, T Hielscher, B Liechty, J Silverman, D Zagzag, R Sen, P Wu, ... Acta neuropathologica 135, 955-963, 2018 | 151 | 2018 |
| Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery PJ Cimino, M Zager, L McFerrin, HG Wirsching, H Bolouri, B Hentschel, ... Acta neuropathologica communications 5, 1-14, 2017 | 116 | 2017 |
| Predicting outcome of epilepsy after meningioma resection HG Wirsching, C Morel, C Gmür, MC Neidert, CR Baumann, A Valavanis, ... Neuro-oncology 18 (7), 1002-1010, 2016 | 92 | 2016 |
| Mutational patterns and regulatory networks in epigenetic subgroups of meningioma N Paramasivam, D Hübschmann, UH Toprak, N Ishaque, M Neidert, ... Acta neuropathologica 138, 295-308, 2019 | 82 | 2019 |
| Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial HG Wirsching, G Tabatabai, U Roelcke, AF Hottinger, F Jörger, A Schmid, ... Annals of oncology 29 (6), 1423-1430, 2018 | 82 | 2018 |
| Thymosin beta 4 gene silencing decreases stemness and invasiveness in glioblastoma HG Wirsching, S Krishnan, AM Florea, K Frei, N Krayenbühl, ... Brain 137 (2), 433-448, 2014 | 57 | 2014 |
| Anti–PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma CI Ene, SA Kreuser, M Jung, H Zhang, S Arora, K White Moyes, ... Neuro-oncology 22 (5), 639-651, 2020 | 52 | 2020 |
| Increased HOXA5 expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma PJ Cimino, Y Kim, HJ Wu, J Alexander, HG Wirsching, F Szulzewsky, ... Genes & development 32 (7-8), 512-523, 2018 | 52 | 2018 |
| The role of molecular diagnostics in the management of patients with gliomas HG Wirsching, M Weller Current treatment options in oncology 17, 1-16, 2016 | 46 | 2016 |
| Mitotic index thresholds do not predict clinical outcome for IDH-mutant astrocytoma RA Yoda, T Marxen, L Longo, C Ene, HG Wirsching, CD Keene, ... Journal of Neuropathology & Experimental Neurology 78 (11), 1002-1010, 2019 | 42 | 2019 |
| Plinabulin, an inhibitor of tubulin polymerization, targets KRAS signaling through disruption of endosomal recycling PJ Cimino, L Huang, L Du, Y Wu, J Bishop, J Dalsing-Hernandez, ... Biomedical reports 10 (4), 218-224, 2019 | 35 | 2019 |
| Copy number profiling across glioblastoma populations has implications for clinical trial design PJ Cimino, L McFerrin, HG Wirsching, S Arora, H Bolouri, R Rabadan, ... Neuro-oncology 20 (10), 1368-1373, 2018 | 31 | 2018 |
| MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from … HG Wirsching, U Roelcke, J Weller, T Hundsberger, AF Hottinger, ... Clinical Cancer Research 27 (1), 179-188, 2021 | 28 | 2021 |
